Therefore, our findings suggest that mRNA-LNP-mediated intratumoral delivery of STINGR284S will allow specific activation of cancer-targeting immune responses in tumor tissues without introducing antiproliferative effects in CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.